Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period

Trial Profile

Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2017

At a glance

  • Drugs ANAVEX 2-73 (Primary) ; ANAVEX 2-73 (Primary) ; ANAVEX-2-73/donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Anavex Life Sciences
  • Most Recent Events

    • 04 Nov 2017 According to an Anavex Life Sciences media release, data from this trial will be presented at the 2017 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
    • 12 Oct 2017 According to an Anavex Life Sciences media release, the company has announced pharmacokinetic (PK) and pharmacodynamic (PD) data from this trial.
    • 12 Oct 2017 According to an Anavex Life Sciences media release, the company is planning to discuss new findings from this trial on the conference call.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top